title: CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
abstract: In order to identify potential markers of renal cancer, the plasma membrane protein content of renal cell carcinoma (RCC)-derived cell lines was annotated using a proteomics process. One unusual protein identified at high levels in A498 and 786-O cells was CD70 (TNFSF7), a type II transmembrane receptor normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types demonstrated strong CD70 staining in RCC tissues. Metastatic tissues from eight of 11 patients with clear cell RCC were positive for CD70 expression. Immunocytochemical analysis demonstrated that binding of an anti-CD70 antibody to CD70 endogenously expressed on the surface of A498 and 786-O cell lines resulted in the rapid internalisation of the antibody-receptor complex. Coincubation of the internalising anti-CD70 antibody with a saporin-conjugated secondary antibody before addition to A498 cells resulted in 50% cell killing. These data indicate that CD70 represents a potential target antigen for toxin-conjugated therapeutic antibody treatment of RCC.
authors.affiliation: Celltech Antibody Centre of Excellence, 216 Bath Road, Slough, Berkshire SL1 4EN, UK.
authors.forename: P J
authors.initials: PJ
authors.lastname: Adam
authors.forename: J A
authors.initials: JA
authors.lastname: Terrett
authors.forename: G
authors.initials: G
authors.lastname: Steers
authors.forename: L
authors.initials: L
authors.lastname: Stockwin
authors.forename: J A
authors.initials: JA
authors.lastname: Loader
authors.forename: G C
authors.initials: GC
authors.lastname: Fletcher
authors.forename: L-S
authors.initials: LS
authors.lastname: Lu
authors.forename: B I
authors.initials: BI
authors.lastname: Leach
authors.forename: S
authors.initials: S
authors.lastname: Mason
authors.forename: A C
authors.initials: AC
authors.lastname: Stamps
authors.forename: R S
authors.initials: RS
authors.lastname: Boyd
authors.forename: F
authors.initials: F
authors.lastname: Pezzella
authors.forename: K C
authors.initials: KC
authors.lastname: Gatter
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D000937:Antigen-Antibody Reactions; D053282:CD27 Ligand / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011485:Protein Binding; D040901:Proteomics / Q000379:methods; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000906:Antibodies; D053282:CD27 Ligand; C505771:CD70 protein, human